Clinical Trial Update: TRAC and Power3 (SPPL3) Genes Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-NHL [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating TRAC and SPPL3 gene-knockout allogeneic CD19-targeting CAR-T cells for relapsed/refractory B-cell non-Hodgkin lymphoma is …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• TRAC and Power3 SPPL3 gene-knockout allogeneic CD19 CAR-T cell therapy

Snippet

Sponsor: Chinese PLA General Hospital | Conditions: Non Hodgkin's Lymphoma | Phase 1, Phase 2 | Status: RECRUITING